BC
JAZZ icon

Bridgefront Capital’s Jazz Pharmaceuticals JAZZ Stock Holding History

Bridgefront Capital’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-2,435
Closed -$310K – 346
2021
Q4 		$310K Buy
+2,435
New +$320K 0.3% 141

Other funds holding JAZZ

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
PCM
Polaris Capital Management Boston, Massachusetts $1.06B AUM 40.82% 1-Year Est. Return
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $181B AUM 41.77% 1-Year Est. Return

Bridgefront Capital's JAZZ Position: Q1 2022 in Review

Bridgefront Capital sold out of Jazz Pharmaceuticals (JAZZ) in Q1 2022, closing a stake of 2,435 shares — an estimated $310K sold.

Bridgefront Capital first reported a position in JAZZ in Q4 2021 and held it in 1 quarter. The position peaked at $310K in Q4 2021. 462 funds tracked by Wall St. Rank hold JAZZ as of Q1 2022.

  • Bridgefront Capital reported no remaining Jazz Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • Bridgefront Capital sold 2,435 Jazz Pharmaceuticals shares in Q1 2022, an estimated $310K.
  • Bridgefront Capital first reported a position in Jazz Pharmaceuticals in Q4 2021 and held it in 1 quarter.
  • Bridgefront Capital's Jazz Pharmaceuticals position peaked at $310K in Q4 2021.
  • 462 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2022.

Based on Bridgefront Capital's 13F filing for Q1 2022, filed 13 May 2022.